^(89)SrCl_2治疗转移性骨肿瘤疼痛的初步临床观察

Preliminary results of therapeutic trial with ^(89)SrCl_2 in skeletal metastases

为了解8 9SrCl2 治疗转移性骨肿瘤的应用价值和不良反应 ,根据89SrCl2 治疗适应征 ,2 5例恶性肿瘤骨转移患者采用静脉注射89SrCl2 1.4 8— 2 .2 2MBq kg(体重 ) ,治疗后每 2周测定白细胞、血小板计数和血生化肝、肾功能指标 ,连续 8— 12周。随访观察患者骨痛的缓解情况和不良反应 ,并进行评判。结果表明 ,2 5例中显效 4例 ,有效 14例 ,无效 7例。前列腺癌、乳癌骨痛缓解疗效较高(分别为 4 4和 6 8) ,总有效率为 72 % ( 18 2 5)。重复治疗仍有疗效 ( 6 6)。疼痛缓解起始时间为2— 14d ,缓解持续时间达 12— 36周。有轻度骨髓抑制反应 ,血液学毒性小于Ⅱ级 ,肝、肾功能血生化指标无明显变化 ,未见出血、胃肠道不适、过敏等不良反应。少数患者 ( 5 2 5)有骨痛闪烁现象。无效可能与多种因素有关。实验结果说明 ,89SrCl2 治疗转移性骨肿瘤对缓解患者的骨痛症状和改善生活质量不失为一种有效、安全的手段 。

To evaluate the safety and efficacy of 89 SrCl 2 in the treatment of painful skeletal metastases of cancer patients. 25 metastatic bony pain patients received 1.48—2.22MBq/kg 89 SrCl 2 intraveneously. After therapy the white blood cell, platelet count, liver and renal function was measured every two weeks during 8—12 weeks. The pain relier and adverse effect were also observed and dose was carried out after 3 months or re-occurrence of pain. Results shown that, pain relief was observed in 18 of 25 patients, among them, complete relief in 4, improved in 14 and no relief in 7. The bony pain responded well in prostate cancer and breast cancer (4/4 and 6/8 respectively), and also effective in repeat treatment (6/6). Pain relief begin from 2—14 days and the duration of pain relief was 12—36 weeks. The toxicity was mild, only transient and restricted to hematological toxicity (<grade II). No adverse reaction, such as bleeding, gastrointestinal symptom and anaphylaxis had been found 5 of 25 patients had pain flar. Conclusions 89 SrCl 2 was an pain-relief agent for skeletal metastases. It can improve the quality of life in the patients and was sate and valuable for clinical use.